Board of Directors

Dr. Frank Wang

Dr. Frank Wang

Chaiperson of the Board

Dr. Frank Wang is currently President, CEO and Founder of BioMedomics, Inc., located at Research Triangle Park, North Carolina. BioMedomics is a biotech company focusing on drug discovery & development, and medical diagnostics. At BioMedomics, Dr. Wang is directly involved in fund raising, corporation operation, marketing and sales.

Ms. Jing Wang

Ms. Jing Wang

Director

Astute leader with expertise across operations management, procurement & supply chain optimization, and financial management.Accomplished and dedicated manager equipped with strong business acumen, financial acuity, and deep knowledge of new product delivery activities management and global supply chain operations. Lead procurement team focusing on new products sourcing decisions with in-depth product cost management knowledge. Analyze and interpret financial records to isolate trends, identify areas for improvement, and assess overall performance.

Mr. Peter Cheng

Mr. Peter Cheng

Director

Mr. Peter Cheng is President of BMP. BMP has delivered tremendous bottom line impact to small, medium and large size North American companies by providing turnkey cost saving solutions. With its strong ties in China, BMP promotes U.S. made products in China and has helped a number of U.S. companies break into China market, a few of which became well known name in its industries in China. With investors from the U.S. and China, BMP has the capability to incubate companies for both U.S. and China clients. BMP has helped inventors turn their ideas into solid business by providing low cost country manufacturing capabilities.

Ms. YanChing Zhang

Ms. YanChing Zhang

Director

I am a PhD physicist / engineer with an extensive background in sales and general management. My passion is with helping my clients to be the most successful in their field, driving a business through collaboration, and am extremely energized with making people around me the best they can be.

Dr. Linxian Wu

Director

Dr. Linxian Wu was born and raised in ChangTing City, Fujian Province, China, and graduated from Xiamen University with a B.Sc. in Microbiology. Dr. Wu has worked in national pharmaceutical and biological product agencies in Beijing, China and Ottawa, Canada, and holds a Ph.D. in Medical Microbiology and Infectious Diseases from the University of Alberta, Canada. Dr. Wu performed his post-doctoral fellow training in Molecular Virology and Immunology at the Medical College of Pennsylvania, where he also remained as a faculty member. Dr. Wu’s scientific credentials include seven USA patents, two EU patents and one World patent, and numerous peer reviewed articles.

Dr. Wu has been further trained in executive programs at Wharton Business School, Stanford University Business School, and INSEAD in Paris, France. He has extensive senior corporate management experience with companies public and private, and with a US subsidiary of a German conglomerate multi-national corporation. His tenure includes the areas of clinical diagnostics, medical devices, biopharmaceuticals and pharmaceuticals. He was the Executive Vice President and Chief Technology Officer of Gull Laboratories, Inc., Salt Lake City, UT, President and Chief Operating Officer of Fresenius Hemocare Inc., Seattle, WA, and President and Chief Operating Officer of Fresenius Kabi Clayton LP, Clayton, NC. He has been an adjunct business professor at the Martha and Spencer Love Business School of Elon University and has taught International Business to MBA students.

Dr. Wu was also the Dean of the BioNetwork Capstone Center of the NC Community College System, had established and managed a consortium program supported by the state of North Carolina to enhance the educational level of North Carolinians in the areas of biopharmaceutical and pharmaceutical operations. In March 2011, Dr. Wu returned to industry and had held the positions of Director of Client Interfacing & Business Development, Director of Biotech and Pharmaceutical Services, and Laboratory Director of Forensic Science at RJ Lee Group Inc., a leading trace materials characterization laboratory and industrial forensics consulting firm (www.rjleegroup.com). After his retirement in May 2015, Dr. Wu has been continuously active professionally and has been selectively taking independent executive consultation projects, including but not limited to advisory capacities for career development and advancement, and the COO functions for BioMedomics, Inc.